Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40

Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
P3 Health Partners Goes Public

P3 Health Partners Goes Public

The private equity-backed P3 Health Partners is going public in a multi-billion-dollar merger with a SPAC.  P3 Health Partners is merging with Foresight Acquisition Corp. (NASDAQ: FORE), and the combined company will have an estimated post-transaction enterprise value of $2.3 billion with an estimated equity value of $2.4 billion from the contribution of at least $180 million in cash proceeds from the transaction. P3 Health Partners was a portfolio company of Chicago Pacific Founders, which is exiting its investment in the company.   P3 Health Partners is a patient-centered and physician-led population health management company that supports providers, physicians and practices as they... Read More »
Charles River Laboratories Buys Vigene Biosciences

Charles River Laboratories Buys Vigene Biosciences

The global contract research organization Charles River Laboratories International, Inc. (NYSE: CRL) is back with a new deal for Vigene Biosciences, Inc. The deal is valued at $292.5 million in cash up front, plus contingent additional payments of up to $57.5 million based on future performance.  Vigene Biosciences is a gene therapy contract development and manufacturing organization (CDMO) providing viral vector-based gene delivery solutions. The acquisition of Vigene Biosciences will enhance Charles River’s gene therapy capabilities in the high-growth, value-added cell and gene therapy CDMO sector. Vigene is expected to generate annual revenue of $30 to $35... Read More »
Thermo Fisher Bets $20 Billion on Leading CRO

Thermo Fisher Bets $20 Billion on Leading CRO

The laboratory and diagnostics giant Thermo Fisher Scientific Inc. (NYSE: TMO) announced a huge deal for an international contract research organization (CRO) last week. Thermo Fisher is buying PPD, Inc. (NASDAQ: PPD), a leading CRO providing broad, integrated drug development, laboratory and lifecycle management services. Its customers include pharmaceutical, biotechnology, medical device, academic and government organizations. The company has offices in 47 countries and more than 26,000 employees. Its headquarters is based in Wilmington, North Carolina.  Thermo Fisher is offering $17.4 billion for PPD, or $47.50 per share for the company, a premium of approximately... Read More »
The MOB Market Heats Up

The MOB Market Heats Up

The market for medical office buildings (MOB) showed plenty of activity in 2020, and that doesn’t seem to be slowing down in 2021. According to search results in our Healthcare Deals Database, there have been 18 transactions announced since January 1, driven primarily by announcements from Montecito Medical Real Estate, which reported nine of those deals.  Montecito Medical, one of the largest privately-held companies specializing in healthcare-related real estate, added nearly 350,000 square feet in property across eight states. One of the most notable purchases was for a three-story, 91,300 square-foot facility in Sandusky, Ohio. The property is 100% leased to Northern Ohio Medical... Read More »
DocGo Goes Public Via SPAC

DocGo Goes Public Via SPAC

Another week, another SPAC deal. Ambulnz, Inc., dba DocGo, has announced it is merging with Motion Acquisition Corp. (NASDAQ: MOTN), a special purpose acquisition company to create a publicly traded entity. DocGo, based in New York City, provides last-mile telehealth and integrated medical mobility services. Its medical mobility services offer on-demand service response and real-time vehicle location, as well as accurate estimated arrival times. The company serves 23 states in the U.S. and has operations in the U.K. By going public, DocGo hopes to continue growing its geographic footprint.  The combined company has a pro forma equity value of approximately $1.1 billion and will have... Read More »
CROs Are Back in Demand

CROs Are Back in Demand

Last year was not kind to contract research organizations (CROs). CROs typically provide discovery and development services to companies in the Medical Device, Pharmaceutical and Biotechnology sectors, conducting clinical trials and providing a wealth of R&D support. Demand for their services have seen a gradual rise over the last decade for a variety of reasons. An increasing number of start-ups have popped up in the Biotechnology sector, and they don’t have the resources or infrastructure that major players would have to oversee the complex R&D needed to bring a drug to market, so they often outsource much of that task to CROs. Second, big pharma and biotech are increasingly... Read More »